参松养心胶囊联合小剂量琥珀酸美托洛尔缓释片对冠状动脉介入术后心律失常的疗效及炎性因子的影响

Abstract
Figure/Table
References (16)
Related Citation (10)

Download: PDF (0 KB) HTML (37 KB)
Export: BibTeX | EndNote (RIS)

Abstract ObjectiveTo observe the effect of Shensong Yangxin Capsule combined with low-dose Metoprolol Succinate Sustained-release Tablets on arrhythmia and inflammatory factors after percutaneous coronary intervention(PCI).MethodsFrom May 2013 to May 2016，134 patients with arrhythmia after PCI in Guangzhou Traditional Chinese and Western Medicine Hospital and the Affiliated Hospital of Guangdong Medical University were divided into three groups by a random number table including Metoprolol Succinate Sustained Release Tablet group(group A;n=46;47.5 mg each time，and once per day)，Shensong Yangxin Capsule group(group B;n=45;3 capsules each time and thrice per day)，and Shensong Yangxin Capsule combined with low-dose Metoprolol Succinate Sustained Release Tablets(group C;n=43;3 Shensong Yangxin capsules each time and three times per day together with 23.75 mg Metoprolol Succinate Sustained release tablet，once per day).The follow-up visits were lasted for 3 months.The incidence of arrhythmia and inflammatory factor levels including high-sensitivity C-reactive protein(hs-CRP)，tumor necrosis factor-α(TNF-α)and interleukin-6 (IL-6)before and after therapy were compared.ResultsCompared with prior treatment，the incidence of arrhythmia and inflammatory factor levels after surgery among three groups were all lower(P＜0.05).By inter-group comparisons，the incidence of arrhythmia was lowest in group C(P＜0.05)，and the levels of hs-CRP，TNF-α and IL-6 in group C were significantly decreased(P＜0.05).ConclusionCombination of Shensong Yangxin Capsule and low-dose of Metoprolol Succinate Sustained Release Tablets can effectively reduce the incidence of arrhythmia after PCI and decrease the inflammatory response.

Key words： Shensong Yangxin Capsule Metoprolol succinate Sustained-release Tablet Percutaneous coronary intervention Arrhythmia Inflammatory factors

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YE Shao-qiang
	JIANG Shou-tao
	HUANG Rui-na

Cite this article:

YE Shao-qiang,JIANG Shou-tao,HUANG Rui-na. Influence of Shensong Yangxin Capsule combined with low-dose Metoprolol Succinate Sustained-release Tablets on arrhythmia and inflammatory factors after percutaneous coronary intervention[J]. 中国当代医药, 2017, 24(19): 36-38转43.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2017/V24/I19/36

[7]	张大鹏，葛永贵，王乐丰，等.急性ST段抬高心肌梗死急诊介入治疗后心肌再灌注不良对近、远期预后的影响[J].中华心血管病杂志，2010，38（6）：488-492.
[8]	李公信，傅向阳，刘映峰，等.冠脉再灌注治疗对心肌梗塞心律失常转归的影响[J].实用医学杂志，2001，17（4）：299-300.
[9]	韦迎娜，周祥群，王芳.胺碘酮防治急性心肌梗塞患者PCI术后心律失常效果分析[J].海南医学，2014，25（18）：2728-2729.
[3]	胡司淦，徐玮，王本芳，等.老年阵发性室上速食道调搏与药物复律的比较[J].中华全科医学，2013，2（3）：9-12.
[4]	杨林，杨颖，王霞.参松养心胶囊联合琥珀酸美托洛尔缓释片治疗室性早搏的疗效观察[J].中国医药指南，2016,14（18）：203-204.
[5]	钱慕仪.抗心律失常药研究新进展[J].当代医学，2010，16（4）：22-25.
[6]	胡占军，徐良，王利清，等.参松养心胶囊对急性冠脉综合征伴心律失常患者临床疗效观察[J].解放军预防医学杂志，2016，34（S3）：155-157.
[1]	王大英，杨克教.冠状动脉支架术后再狭窄相关因素分析[J].上海医学，2007，30（Z1）：118-119.
[2]	李涛.急性心肌梗死介入治疗与药物治疗疗效的临床观察[J].中西医结合心血管病杂志，2014，2（10）：48-49.
[10]	Zhang ZW，Lin ZP.Response to metoprolol succinate sustained-release tablets in correlation to pulse pressure，serum vascular endothelial growth factor and C-reactive protein in elderly hypertensive patients with chronic heart failure[J]. Nan Fang Yi Ke Da Xue Xue Bao，2010，30（9）：2171-2174．
[11]	高洁.琥珀酸美托洛尔和非洛地平及盐酸贝那普利治疗单纯收缩期高血压的疗效观察[J].实用心脑肺血管病杂志，2013，21（2）：70-71.
[12]	杨东伟，刘新叶，池豪，等.不同剂型美托洛尔治疗慢性心力衰竭的临床疗效观察[J].实用心脑肺血管病杂志，2013，21（3）：15-16.
[13]	Li N，Ma K，Wu XF，et al.Effects of Chinese herbs on multiple ionchannels in isolated ventricular myocytes[J].Chin Med J（Engl），2007，120（12）：1068-1074.
[14]	黄华文，周宏霞，梁燕运.参松养心胶囊联合酒石酸美托洛尔胶囊治疗老年心律失常的疗效观察[J].广东医学院学报，2011，29（6）：655-656．
[15]	王晞，段慧楠，胡娟，等.参松养心胶囊对心功能及心脏电生理影响的实验研究[J].中华心律失常学杂志，2012，16（6）：417-421.
[16]	胡峻强，张善芳.参松养心胶囊治疗急性冠状动脉综合征并心律失常的疗效观察[J].医学临床研究，2015，32（5）：922-924.